Learning Objective  To understand the rationale for prophylactic human papillomavirus (HPV) vaccination with GARDASIL™. GARDASIL is a trademark of Merck.

Slides:



Advertisements
Similar presentations
The Future is Now: Understanding the HPV Vaccine Guidelines E.J. Mayeaux, Jr., M.D. Professor of Family Medicine Professor of Obstetrics and Gynecology.
Advertisements

Human Papillomaviruses (HPV): The Background, Current Status and Future of Vaccines to Prevent HPV Infection, Abnormal Genital Lesions and Cervical Cancer.
Group 3 – Michael, Elani, Golshan, Sarah, Joseph, Nana
HPV-vaccines – a breakthrough in medicine Björn Strander Onkologiskt centrum Västra regionen and Kungsbacka Närsjukhus Sweden.
HPV Vaccines: What We Know and What We Should Expect Laura Koutsky, PhD Professor of Epidemiology University of Washington Seattle, WA.
Prevention of Cancer Cervix by Vaccination
The journey of HPV vaccine : From Study to Real world experience
HPV Vaccine Update Eileen Yamada, MD, MPH Immunization Branch California Department of Health Services.
Development of the HPV 16 / 18 Cervical Cancer Vaccine
You are the Key to HPV Cancer Prevention Understanding the Burden of HPV Disease, the Importance of the HPV Vaccine Recommendation, and Communicating about.
A Cost-Effectiveness Analysis of Alternative Human papillomavirus ( HPV) Vaccination Strategies Elamin H. Elbasha Merck Research Laboratories, USA.
The HPV Vaccine Our Best Shot to Prevent Cervical Cancer Harold C. Wiesenfeld, MD,CM Department of Obstetrics, Gynecology and Reproductive Sciences-University.
1 Cervical Cancer & HPV Mary Applegate, MD MPH Interim Dean UAlbany School of Public Health February 15, 2007.
What is HPV? Estimated to be the most common sexually transmitted infection in the United States.
Anticipated impact on HPV infection from HPV vaccination programs – cause for optimism Dr Paddy Horner.
Jennifer S. Smith University of North Carolina Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical.
Our memories of Mahabaleswar. CDC - Immunization Update 2006 Satellite Internet Broadcast December, 2006 Cervical Cancer Vaccine - HPV Summarized from.
Human Papillomavirus Heidi M. Bauer, MD MPH California Department of Health Services STD Control Branch.
1 Use of GARDASIL ® in Boys and Men Vaccines and Related Biological Products Advisory Committee Meeting September 9, 2009 Merck Research Laboratories.
HPV Vaccine – Does it Prevent Cervical Cancer?
HPV Vaccination - the end of the road for cervical cancer? Alison Fiander Wales College of Medicine Cardiff University.
HPV: How to prevent your patients from becoming my patients Katina Robison, MD Assistant Professor, Department of Obstetrics & Gynecology Director of Colposcopy.
Cervical Cancer By:Marisela Esparza. Cervical Cancer is cancer in the cervix (the lower part of the cervix that connects to the vagina.)
Human Papilloma Virus (HPV) Vaccine.  HPV infection conveys risk of anogenital warts and local symptoms like itch and pain  High risks include cervical.
Immunisation Against Human Papilloma Virus David Green – Immunisation Co- ordinator and Infection Control Nurse.
Human Pappiloma Virus DsDNA, Circular genome
ADOLESCENT IMMUNIZATIONS
Prospects for a Prophylactic HPV Vaccine and Future Implications for Cervical Cancer Screening Dr. Fuat Demirkıran İ.Ü Cerrahpaşa Tıp Fak. Kadın Hast.
Poster template by ResearchPosters.co.za The efficacy of bivalent and tetravalent HPV vaccination against cervical intraepithelial neoplasia and persistent.
Gardasil Nicole Kettner, Guy Hamilton, Nathalie Besse.
J. Kahn, J. Xu, B. Kapogiannis, B. Rudy, N. Liu, R. Gonin, C. Wilson, C. Worrell, K. Squires, and the Adolescent Medicine Trials Network for HIV/AIDS Interventions.
HPV Related Disease Ginny Ryan. What Is HPV? The human papillomavirus is the most common sexually transmitted infection in the U.S. – 79 million Americans.
Minnesota Department of Health
Prophylactic HPV vaccines to prevent cervical cancer —but what else? Aimee R. Kreimer, Ph.D. National Cancer Institute March 20,
Herpes Papillomavirus (HPV) and Varicella-zoster Virus (VZV) Vaccination Ellen Barbouche, MD Primary Care Conference 18 April 2007.
Learning Objective  To know the results of the clinical trial, immune response and duration, and efficacy analysis for GARDASIL™. 1 GARDASIL is a trademark.
Burden of Disease Professor Xavier Bosch Institut Català d’Oncologia Barcelona, Spain.
Learning Objectives  Establish the high global prevalence of HPV infection and HPV-related diseases. 1.
The New HPV Vaccine Laura Zakowski, MD No conflicts of interest.
GENITAL WARTS/CANCER HPV GENITAL WARTS/CANCER Giulia De Vettori SLCC Bio 1010 Period 6.
Breast cancer 5 year survival rates (UK, 1975) by stage at diagnosis.
Slide 1 Downloaded from Population Impact of Losartan Use on Stroke in the European Union (EU)
The Second Cancer Vaccine: Human Papillomavirus Vaccine Meg Fisher, MD Medical Director.
Cervical Cancer, HPV and Prophylactic Vaccines Paulo Naud.
GARDASIL Vaccination HEALTH PROMOTION PROJECT BRANDI MALSY DECEMBER 3, 2014.
Human Papillomavirus (HPV) Vaccines: Addressing Safety & Efficacy – Promoting Adolescent Immunization James H. Conway, MD FAAP Professor of Pediatrics.
HPV and Pap Guidelines Jennifer Johnson MD. Objectives 1. Define the new PAP guidelines. 2. Identify the historical trends and new evidence resulting.
Preventing Cervical Cancer: Human Papillomavirus (HPV) Vaccine
HPV-related anogenital cancers
Epidemiology of HPV Infection Eileen Dunne MD, MPH Division of STD Prevention, CDC February, 2006.
HPV Vaccines Update on ACIP Recommendations National Immunization Conference April 20, 2010 Lauri E. Markowitz, MD Centers for Disease Control and Prevention.
Chapter 29 Human Papilloma Virus Infection and Immunity.
Update on HPV vaccines and recommendations - Lauri Markowitz Plans for monitoring impact of HPV vaccine - Eileen Dunne Uptake of HPV vaccine, ISS Sentinel.
Update on HPV Vaccines National Immunization Conference April 1, 2009 Lauri E. Markowitz, MD Centers for Disease Control and Prevention.
HPV Vaccine is Cancer Prevention
Cancers Linked to HPV Presenter: Chuck Lynch
Division of STD Prevention, CDC
Principles of HPV vaccination Some derived from Phase III trials Some are based on clinical judgement / research HPV vaccines have no contraindications.
HPV Vaccines and Data Needed for Development of Recommendations in the United States Lauri E. Markowitz, MD Centers for Disease Control and Prevention.
HPV VACCINES Dr. Kirtan Krishna.
HPV Tajossadat Allameh Associated Profeesor of Ob& Gyn
Adolescent Immunization Update
Overview HPV and HPV Vaccines
Dr Sam Hibbitts HPV Research Team Obstetrics & Gynaecology
World Health Organization
Nat. Rev. Clin. Oncol. doi: /nrclinonc
World Health Organization
Research Update: The HPV Vaccines
Rotavirus Vaccines An Update
Presentation transcript:

Learning Objective  To understand the rationale for prophylactic human papillomavirus (HPV) vaccination with GARDASIL™. GARDASIL is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA. 1

Cervical Cancer Mortality/100,000 3 Cervical Cancer Incidene/100, Cervical Cancer Occurs Despite Established Screening Programs Example of Europe 1. Anttila A, Ronco G, Clifford G, et al. Br J Cancer. 2004;91:935– van Ballegooijen M, van den Akker-van Marle E, Patnick J, et al. Eur J Cancer. 2000;36:2177– Ferlay J, Bray F, Pisani P, Parkin DM. Lyon, France: IARC Press; 2004.CountryRecommendation % Regularly Screened Age Range (Years) Interval (Years) Finland 1 30–60593 England 1 25–643–53–583 Sweden 1 23–60383 Belgium 2 25–64378 The Netherlands 1 30–60577 Denmark 1 23–59375 France 1 25–65369 Italy 1 25–64353–74 Germany 1 20–85150 Spain 2 25–

Targeting High Disease Burden With GARDASIL™ TypeWomenMen 6/11  >90% of genital warts 2  ~10% of low-grade cervical lesions 3  Recurrent respiratory papillomatosis (RRP)*,4  Transmission to men 5  >90% of genital warts 2  Transmission to women 9  RRP*,4 16/18  ~70% of cervical cancer 3  ~50% of high-grade cervical lesions 6  ~25% of low-grade cervical lesions 3  ~70% of high-grade vulvar/vaginal lesions 7  Oropharyngeal cancer †,8  Other cancers †,8  Transmission to men 5  ~60% of anal cancer 10  Penile cancer †,8  Oropharyngeal cancer †,8  Other cancers †,8  Transmission to women 9  Targeting HPV types 6, 11, 16, and 18 with GARDASIL is expected to substantially reduce the burden of HPV-related diseases Villa LL, Costa RLR, Petta CA, et al. Lancet Oncol. 2005;6:271– Gissmann L, Wolnik L, Ikenberg H, et al. Proc Natl Acad Sci USA. 1983;80:560– Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Cancer Epidemiol Biomarkers Prev. 2005;14:1157– Kashima HK, Mounts P, Shah K. Obstet Gynecol Clin North Am. 1996;23:699– Dunne EF, Nielson CM, Stone KM, et al. J Infect Dis. 2006;194:1044– Clifford GM, Smith JS, Aguado T, Franceschi S. Br J Cancer. 2003;89:101– GARDASIL Worldwide Product Circular. Merck & Co., Inc., Whitehouse Station, NJ, USA. 8. Parkin DM. Int J Cancer. 2006;118:3030– Castellsagué X, Bosch FX, Muñoz N. Salud Publica Mex. 2003;45(suppl 3):S345– Frisch M, Glimelius B, van den Brule AJC, et al. N Engl J Med. 1997;337:1350–1358. *GARDASIL TM is not indicated for RRP; † Undetermined proportion GARDASIL is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA. 3

HPV Types 6, 11, 16, and 18 in Cervical Cancer and Other Anogenital Diseases Prevalence of HPV Type 1. Clifford GM, Rana RK, Franceschi S, et al. Cancer Epidemiol Biomarkers Prev. 2005;14:1157– Clifford GM, Smith JS, Aguado T, et al. Br J Cancer. 2003;89:101– Muñoz N, Bosch FX, de Sanjosé S, et al. N Engl J Med. 2003;348:518– Clifford GM, Smith JS, Plummer M, et al. Br J Cancer. 2003;88:63– Gissmann L, Wolnik L, Ikenberg H, et al. Proc Natl Acad Sci USA. 1983;80:560– ,3,4 5 4

GARDASIL™: The First Cervical Cancer Vaccine  HPV types 6, 11, 16, 18 1  Recombinant vaccine (does not contain live virus) 1  Manufactured in Saccharomyces cerevisiae 1 – Yeast-derived vaccines given to millions of children and adults 2  Proprietary aluminum adjuvant 225 μg per dose 1  Each 0.5-mL injection volume contains HPV types 6/11/16/18 (20/40/40/20 μg, respectively) 1  Intramuscular administration 1  0-, 2-, 6-month dosing regimen 1 GARDASIL is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA. 1. GARDASIL Worldwide Product Circular. Merck & Co., Inc., Whitehouse Station, NJ, USA. 2. Unger ER, Barr E. Human papillomavirus and cervical cancer [conference summary]. Emerg Infect Dis [serial on the Internet] Nov [Cited October 19, 2006]. Available from Accessed April 26,

Central/South America Northern Africa North America/ Europe South Asia HPV Type 52 Others *A pooled analysis and multicenter case control study (N = 3607) Muñoz N, Bosch FX, Castellsagué X, et al. Int J Cancer. 2004;111:278–285. Worldwide Prevalence of HPV Types in Cervical Cancer *

HPV and Anogenital Warts  HPV types 6 and 11 responsible for >90% of anogenital warts 1  Estimated lifetime risk of developing genital warts ~10% 2,3  External genital warts are very contagious. 4  Infectivity >75% 1. Jansen KU, Shaw AR. Annu Rev Med. 2004;55:319– Franco EL, Villa LL, Richardson H, et al. In: Franco EL, Monsonego J, eds. Oxford, UK: Blackwell Science; 1997:14– Tortolero-Luna G. Hematol Oncol Clin North Am. 1999;13:245–257, x. 4. Soper DE. In: Berek JS, ed. Novak’s Gynecology. 13th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002:453–470. Images top left and top right: Reprinted with permission from NZ DermNet ( 7

Necessary criteria Possible End Points HPV Infection CIN* 1 CIN 2/3 Required precursor for cervical cancer √—√ Prompts treatment——√ Reduction leads to cervical cancer reduction —— √ Clinical Program for GARDASIL™: Selection of Trial End Points 1–3 1. Pagliusi SR, Aguado T. Vaccine. 2004;23:569– GARDASIL Worldwide Product Circular. Merck & Co., Inc., Whitehouse Station, NJ, USA. 3. Lowy DR, Frazer IH. Chapter 16: Prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr. 2003:111–116. CIN 2/3 are World Health Organization (WHO) – recommended surrogate end points for HPV vaccine trials. 1 Surrogate end points are required because it is unethical to wait for the development of cervical cancer. 3 8 *CIN = cervical intraepithelial neoplasia GARDASIL is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA.

GARDASIL™ Yields Higher Neutralizing Anti-HPV Antibodies in Baseline Seropositive Subjects GMT** (mMU/mL) Log 10 Scale ***PCR = polymerase chain reaction Villa LL, Ault KA, Giuliano AR, et al. Vaccine. 2006;24:5571– Month (n=14) (n=177) (n=15) (n=170) 9 *vaccination **GMT = geometric mean titer * * * Vaccine: naïve recipient Placebo: naïve recipient Vaccine: seropositive and PCR*** -negative recipient Placebo: seropositive and PCR-negative recipient

GARDASIL™ (20/40/40/20 μg) Neutralizing Anti-HPV Immunogenicity In a double-blind, placebo-controlled, dose-ranging study of quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine HPV 6 *** HPV 11 *** Time Since Vaccination (Months) ,000 GMT with 95% CI mMU/mL (Log Scale) ** * HPV 18 *** HPV 16 Per-Protocol Subjects (GARDASIL) * vaccination GARDASIL is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA. Adapted from Olsson S-E et al. Vaccine. 2007;25:4931–

GARDASIL™ Demonstrated Immune Memory Antibodies were built up during the 3-dose vaccination series. When tested by antigen challenge, vaccinated subjects demonstrated classic immune memory—the hallmark of long-term protection. 1 Minimum protective level of antibodies is defined through breakthrough cases. Through five years, there were no breakthrough cases for GARDASIL, while there were continuing infections for placebo Time (months) VVVA Anti-HPV 16 response (GMT levels with 95% CI) Immune memory response was proven by antigen challenge 1 GARDASIL n=78 placebo n=70 12 Time Antigen challenge A Antigen challenge at month 60 Vaccination series for GARDASIL V Vaccination at day 0, month 2, and month 6 Antibody levels stabilized through at least five years… and counting Data on file, MSD. 11 GARDASIL is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA.

HPV 6, 11, 16, or 18-related GARDASILPlacebo NCasesNCasesEfficacy 95% CI Persistent Infection 2352* %(83, 100) Disease %(12, 100) CIN 1, 2, or %(<0, 100) Vulvar/Vaginal Neoplasias or Genital Warts %(<0, 100) GARDASIL™: Durable Protection Through Five Years A total of 241 subjects were entered into the five-year extension phase of Protocol 007. *One case of confirmed persistent infection: HPV 18 DNA detected at months 12 and 18 only (not a case in the five-year extension). *One case of HPV 16 DNA detected at the last visit (month 36); not a subject in the five-year extension phase. GARDASIL is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA. Villa LL, Costa R, Petta R, et al. Br J Cancer. 2006;95:1459–1466. Per-protocol efficacy population Subjects were naïve to HPV types 6, 11, 16, and/or 18 12

GARDASIL is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA. GARDASIL™ TOLERABILITY  Vaccination was generally well tolerated. The most common adverse event was local discomfort at the injection site.  There were no discontinuations due to serious vaccine-related adverse events. 13

Select Information About GARDASIL TM  GARDASIL is a vaccine indicated in girls and women 9 to 26 years of age for the prevention of cervical cancer, precancerous or dysplastic lesions, and genital warts caused by HPV Types 6, 11, 16, and 18.  GARDASIL is contraindicated in individuals who are hypersensitive to the active substances or to any of the excipients of the vaccine.  GARDASIL does not substitute for routine cervical cancer screening, and women who receive GARDASIL should continue to undergo screening per standard of care.  Vaccination with GARDASIL may not result in protection in all vaccine recipients.  GARDASIL has not been shown to protect against diseases due to non- vaccine HPV types.  GARDASIL is not intended to be used for treatment of active genital warts; cervical cancer; CIN, VIN, or VaIN.  The vaccine-related adverse experiences that were observed among recipients of GARDASIL at a frequency of at least 1.0% and greater than placebo were pain, swelling, erythema, fever, nausea, pruritus, and dizziness.